Advanced Therapy Medicinal Product (ATMP)
The current of cancer development in each patient differs. Despite the fact that drug formulations in the field of cancer chemotherapy are accompanied by many innovations every year, conducted developments have not yet been able to eliminate or reduce its side effects. Due to this situation, According to the mentioned cases, there is a need to create a new chapter of medical treatments that increase the chances of patients' recovery and reduce the unwanted side effects of common treatments by using new technological methods. These advanced treatments are being developed using the latest technologies in the fields of genetic engineering, cell science, virology, immunology and tissue engineering. Products that can be used as a complementary medicine and in some cases as a main treatment method in eradicating refractory cancers and increasing patient survival. These technologies are classified in a new field called Advanced Therapy Medicinal Products (ATMP).
ATMP field contains a diverse spectrum of innovative technologies in which with conducting cellular methods, genetic engineering and tissue engineering, biological products are produced to treat diseases. The products that are produced from advanced treatments recently obtained some permissions from the US and EU health care systems for the treatment of incurable diseases such as cancer, immunodeficiency diseases, nerve palsy, stroke and diabetes.
European Medicines Agency divides advanced therapies into three main categories:
- Cell Therapy Medicinal Product, CTMP
- Gene Therapy Medicinal Product, GTMP
- Tissue Engineered Products, TEF